Pleiotropy, the phenomenon where one gene affects multiple traits, appears to be pervasive in biology. For example, findings from genome-wide association studies (GWAS) demonstrate that GWAS loci for different traits overlap nearly 50% of the time ([@B2]). Often these traits are related, as is illustrated by GWAS of endometrial cancer risk, where all 16 known loci contain variation that has been associated with other traits, including susceptibility to other cancer types as well as known risk factors for endometrial cancer (e.g., body mass index and age of menarche) ([@B10]).

Recently, it has been shown that drugs with genetically supported targets, including those identified by GWAS, are more likely to receive clinical approval than drugs whose targets are not supported by genetic evidence ([@B9]; [@B8]). This effect is strongest when the causal gene underlying the genetic association has been established (e.g., Mendelian genes), highlighting an inherent problem with clinical translation of findings from GWAS, i.e., identifying the target genes of, primarily, non-coding genetic variation ([@B3]; [@B10]). Even though a variety of bioinformatic and functional genomic approaches can be used for this purpose, and many data are publicly available ([Pritchard et al.](https://doi.org/10.3389.fphar.2017.00896)), this step appears to constitute a major bottleneck ([@B5]).

It has been estimated that 4,479 human genes encode proteins that are druggable, 1,427 of which are targets of drugs that either have been approved or are in clinical testing ([@B4]). In light of these and the observations above, the human genome may provide a source of effective targets for therapy. Furthermore, many public databases, using various types of evidence, can be queried to link genes to drugs or experimental compounds ([Pritchard et al.](https://doi.org/10.3389.fphar.2017.00896)). It is thus apparent that if a genetic study of disease identifies a target for which a drug already exists, then that drug may be able to be repurposed (or repositioned) to treat or serve as co-therapy to the new indication. Drug repurposing is not without caveats, though. The repurposed drug may still need to undergo pre-clinical validation ([Pritchard et al.](https://doi.org/10.3389.fphar.2017.00896)) before the repurposing is tested clinically, especially if there is limited evidence to demonstrate that the drug affects the function of the target. Also, issues with the patentability mean drug repurposing may be of less interest to pharmaceutical companies ([Pritchard et al.](https://doi.org/10.3389.fphar.2017.00896)).

As well as providing further indications for drug repurposing, pleiotropic drug targets may offer additional support for targeting. An example of such a pleiotropic target is provided by *CYP19A1*. Endometrial cancer GWAS risk variation at the *CYP19A1* gene also associates with circulating estradiol, which itself is causal for endometrial cancer ([@B13]). *CYP19A1* encodes aromatase, the rate-limiting enzyme in the production of estradiol, which is targeted by aromatase inhibitors (used in the treatment of breast cancer). These drugs have been repurposed to treat endometrial cancer with some evidence of benefit for early-stage but not advanced disease (reviewed in [@B6]). However, it is possible that genetic markers could be used to identify patients with advanced disease who may receive benefit. Pharmacogenetic studies of aromatase inhibitors in breast cancer suggest that genetic variation in linkage disequilibrium with the pleiotropic *CYP19A1* GWAS variation may associate with better outcomes in advanced disease ([Glubb et al.](https://doi.org/10.3389.fphar.2017.00218)), though further studies are required to validate this finding.

Pharmacokinetic-related genes (i.e. those involved with drug absorption, distribution, metabolism, or excretion) are very often pleiotropic because they can affect traits related to exposure to multiple drugs or xenobiotics. Two examples are *CYP2C19* and *SLCO1B1*, which are associated with drug metabolism and transport, respectively. Both genes are highly pleiotropic with *CYP2C19* and *SLCO1B1* having been associated with responses to large numbers of drugs (588 for *CYP2C19* and 56 for *SLCO1B1*) ([@B1]), including the pharmacokinetic profile of the antiplatelet agent ticagrelor as described in the current Research Topic ([Zhu et al.](https://doi.org/10.3389.fphar.2019.00209)) Further analysis of these two genes, and their pharmacogenetic variants, in phenome-wide association studies demonstrates that their pleiotropy may extend to the risk of common disease ([@B11]).

*TRIB3* is another pleiotropic gene with potential to inform drug therapy. A *TRIB3* missense variant (rs2295490) has been associated with early-onset type 2 diabetes, higher glucose levels in healthy controls ([@B12]), and reduced risk of vascular events among type 2 diabetes patients with good glucose control ([@B7]). A study of patients with essential hypertension, presented in this Research Topic, indicates that rs2295490 may also associate with better vascular outcomes for patients treated with calcium channel blockers, angiotensin blockers, and α, β-adrenoceptor antagonists ([Zhou et al.](https://doi.org/10.3389.fphar.2019.00236)).

In conclusion, it is evident that pleiotropy offers the potential to identify drugs to treat common disease, and pleiotropic targets have advantages, particularly over those with no genetic basis. Moreover, establishing pleiotropy may provide an approach to prioritize targets for evaluation and identify genes that also affect clinical drug responses.
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